CSL Behring: Clinical Trials

50 completed, 9 terminated, 6 recruiting, 1 withdrawn. 66 Phase 3, 9 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	66	Completed 50, Terminated 9, Recruiting 6, Withdrawn 1
Phase 2	9	Completed 6, Terminated 2, Recruiting 1

Follow CSL Behring: new trials by email

Trials (filtered) newest first · largest first

All 66 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies IgPro20 - Secondary Immune Deficiency	Phase 3	Recruiting	CSL Behring	63	2026-09-15	2026-10-14
Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB) BE1116, FFP - Complex Cardiovascular Surgery With Cardiopulmonary Bypass	Phase 3	Recruiting	CSL Behring	200	2025-09-15	2026-10-15
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B CSL222 (Adeno-associated viral vector serotype 5 [AAV5]-hFIXco-Padua) - Hemophilia B	Phase 3	Recruiting	CSL Behring	20	2025-07-28	2026-10-20
Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products Recombinant single-chain factor VIII (rVIII-SingleChain) - Congenital Hemophilia A	Phase 3	Completed	CSL Behring	62	2025-01-09	2026-10-23
Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery CSL511 Fibrinogen concentrate (human), Cryoprecipitate - Acquired Fibrinogen Deficiency	Phase 3	Recruiting	CSL Behring	90	2024-10-01	2026-10-13
Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS IgPro20, Placebo - Post-COVID Postural Orthostatic Tachycardia Syndrome	Phase 3	Terminated	CSL Behring	16	2024-08-28	2026-04-13
Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX Therapy Recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) - Hemophilia B	Phase 3	Completed	CSL Behring	23	2024-07-28	2026-07-23
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) CSL300, Placebo - End Stage Kidney Disease	Phase 2 / Phase 3	Recruiting	CSL Behring	3110	2024-04-27	2026-09-21
Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs) CSL222 (AAV5-hFIXco-Padua) - Hemophilia B	Phase 3	Recruiting	CSL Behring	35	2024-01-30	2026-08-27
CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema CSL312 - Hereditary Angioedema (HAE)	Phase 3	Completed	CSL Behring	22	2023-05-30	2026-06-02
Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study ) BE1116, Placebo - Traumatic Injury	Phase 3	Terminated	CSL Behring	1366	2023-03-28	2025-12-10
Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks CSL312 - Hereditary Angioedema	Phase 3	Completed	CSL Behring	171	2021-03-29	2026-06-02
CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks CSL312, Placebo - Hereditary Angioedema	Phase 3	Completed	CSL Behring	64	2021-01-27	2023-06-29
Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone Alpha-1 antitrypsin (AAT), Placebo - Graft Versus Host Disease (GVHD)	Phase 3	Completed	CSL Behring	136	2020-01-09	2026-07-28
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM) human immunoglobulin G, Placebo - Dermatomyositis	Phase 3	Terminated	CSL Behring	134	2019-10-21	2025-12-09
Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients Clazakizumab, Physiologic saline solution - Antibody-mediated Rejection	Phase 3	Terminated	CSL Behring	194	2019-10-14	2025-07-23
The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant AAT, Placebo - Acute-graft-versus-host Disease	Phase 2 / Phase 3	Terminated	CSL Behring	222	2019-03-27	2026-09-09
Administration of Prothrombin Complex Concentrate vs. Standard Transfusion During/After Heart Transplantation Kcentra, Frozen Plasma Product, Human - Heart Disease End Stage, Heart Failure，Congestive	Phase 3	Terminated	University of Maryland, Baltimore	14	2018-07-11	2025-05-23
HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients AAV5-hFIXco-Padua, Factor IX (FIX) - Hemophilia B	Phase 3	Completed	CSL Behring	67	2018-06-27	2026-03-27
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome Apolipoprotein A-I [human] (apoA-I), Placebo - Acute Coronary Syndrome	Phase 3	Completed	CSL Behring	18226	2018-03-21	2025-01-14

Showing 20 of 66. Sign in to see all of them.

Conditions studied

Hemophilia B (9)  ·  Angioedemas, Hereditary (7)  ·  Hemophilia A (7)  ·  Primary Immunodeficiency Diseases (6)  ·  Agammaglobulinemia (4)  ·  Common Variable Immunodeficiency (4)  ·  Hemostatic Disorders (3)  ·  IgG Deficiency (3)  ·  Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (3)  ·  von Willebrand Diseases (3)  ·  Afibrinogenemia (2)  ·  Atherosclerosis (2)  ·  Blood Coagulation Disorders (2)  ·  Coronary Artery Disease (2)  ·  Factor XIII Deficiency (2)

Interventions

Hizentra (13)  ·  Immunoglobulins, Intravenous (7)  ·  gamma-Globulins (7)  ·  Complement C1 Inhibitor Protein (5)  ·  Factor IX (5)  ·  Fibrinogen (4)  ·  albutrepenonacog alfa (4)  ·  Immunoglobulin G (3)  ·  alpha 1-Antitrypsin (3)  ·  Albumins (2)  ·  Factor VIII (2)  ·  Proline (2)  ·  clazakizumab (2)  ·  cryoprecipitate coagulum (2)  ·  Apolipoprotein A-I (1)

Countries

United States (37)  ·  Germany (30)  ·  Spain (24)  ·  Canada (22)  ·  Italy (21)  ·  United Kingdom (21)  ·  Australia (19)  ·  France (18)  ·  Japan (18)  ·  Poland (18)  ·  Czechia (15)  ·  Israel (15)  ·  Netherlands (14)  ·  Russia (14)  ·  Austria (13)

Top investigators

Andrew J Pollard, FRCPCH, PhD (1)  ·  Arno P Nierich, MD, PhD. (1)  ·  Carmen Escuriola-Ettingshausen (1)  ·  Cynthia L Bristow, PhD (1)  ·  Danielle Duffy, MD (1)  ·  Ingrid Pabinger-Fasching, Prof. (1)

Results publications

PMID 36326435, PMID 40386832, PMID 23987198, PMID 24412910, PMID 40380356, PMID 42268494, PMID 17479360, PMID 18208533, PMID 18814020, PMID 19635187, PMID 19767078, PMID 19787352, PMID 20217199, PMID 20454851, PMID 20674826, PMID 21195947, PMID 21553933, PMID 21674136, PMID 21705277, PMID 21884533, PMID 22856636, PMID 23781960, PMID 23935011, PMID 24229737, PMID 24266596, PMID 24504846, PMID 25377187, PMID 25728933, PMID 26037084, PMID 26135740, PMID 26755710, PMID 27317703, PMID 27330001, PMID 27455854, PMID 27583313, PMID 28241354, PMID 28328347, PMID 28594116, PMID 29122523, PMID 30462259, PMID 30772477, PMID 31485239, PMID 31824943, PMID 32042283, PMID 33332922, PMID 33588897, PMID 35497778, PMID 35969004, PMID 36550562, PMID 36812434

NIH funding

2009 (5), 2023 (5), 2017 (3), 2018 (3), 2004 (2), 2008 (2), 2014 (2)